Translate Bio, Inc. (TBIO): IPOs News

TBIO – Company has priced an up-sized 9.4mm shares at $13.00.


Key Facts Surrounding This News Item


  • TBIO had returned 0.00% year-to-date leading up to today’s news, versus a +1.79% return from the benchmark S&P 500 during the same period.

More Info About Translate Bio, Inc. (TBIO)


Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is based in Lexington, Massachusetts. View our full TBIO ticker page with ratings, news, and more.

TBIO at a Glance

TBIO Current POWR Rating™
Overall POWR Rating™
TBIO Current Price $6.29 5.01%
More TBIO Ratings, Data, and News

TBIO Price Reaction

The day of this event (Jun. 28, 2018)
TBIO Closing Price$11.52 N/A%
TBIO Volume3,053,300
N/A% from avg
Leading up to this event
TBIO 1-mo returnN/A%
After this event
TBIO 1-day returnN/A%
TBIO 3-day returnN/A%
TBIO 5-day returnN/A%

TBIO Price Chart



More Translate Bio, Inc. (TBIO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TBIO News
Page generated in 0.6779 seconds.